Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

Cancer

Volumn 120, Issue 24, 2014, Pages 3940-3951

  Saba, Nabil F ^a   Hurwitz, Selwyn J ^a   Magliocca, Kelly ^a   Kim, Sungjin ^b   Owonikoko, Taofeek K ^a   Harvey, Donald ^a   Ramalingam, Suresh S ^a   Chen, Zhengjia ^b   Rogerio, Jackie ^c   Mendel, Jennifer ^d   Kono, Scott A ^e   Lewis, Colleen ^a   Chen, Amy Y ^a   Higgins, Kristin ^a   El Deiry, Mark ^a   Wadsworth, Trad ^a   Beitler, Jonathan J ^a   Shin, Dong M ^a   Sun, Shi Yong ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

And carboplatin; And NONMEM; Cetuximab; Everolimus; Everolimus in head and neck cancer; Everolimus in squamous cell carcinoma; MTOR inhibition in head and neck cancer; MTOR inhibition in squamous cell carcinoma; Pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P42; PROTEIN P44; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RAPAMYCIN;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LOADING DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SIROLIMUS;

EID: 84919339148     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28965     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Rose BS, Jeong J, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011; 29: 3503-3509.
3. Saba NF, Khuri FR. Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. Curr Opin Oncol. 2009; 21: 232-237.
4. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116-1127.
5. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer. 2008; 98: 923-930.
6. Chinnaiyan P, Won M, Wen PY, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013; 86: 880-884.
7. Avadhani AN, Flaherty K, Rosen M, et al. A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors. J Clin Oncol. 2007; 25: 14075.
8. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006; 12: 5064-5073.
9. Crowley J, Hoering A. Handbook of Statistics in Clinical Oncology. 3rd ed. Boca Raton, FL: CRC Press; 2012.
10. Ciunci CA, Perini RF, Avadhani AN, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 2014; 120: 77-85.
11. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12: 601-609.
12. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009; 15: 1612-1622.
13. Klumpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. Oncologist. 2010; 15: 1262-1269.
14. Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer (Auckl). 2013; 7: 7-22.
15. Wurtz R, Itokazu G, Rodvolt K. Antibiotic dosing in obese patients. Clin Infect Dis. 1997; 25: 112-118.
16. Bergstand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13: 143-151.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
18. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
19. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007; 24: 2187-2197.
20. Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013; 119: 3212-3218.
21. Ramalingam SS, Harvey RD, Saba N, et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer. 2010; 116: 3903-3909.
22. James R, Vishwakarma S, Chivukula IV, et al. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs. Cancer Med. 2012; 1: 114-127.
23. Ishikawa D, Takeuchi S, Nakagawa T, et al. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 2013; 8: e62104.
24. Bago-Horvath Z, Sieghart W, Grusch M, et al. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology. 2012; 96: 228-237.
25. Papadimitrakopoulou VA, Soria J, Jappe A, et al. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1594-1601.
26. Kordes S, Richel DJ, Klümpen HJ, Weterman MJ, Stevens AJ, Wilmink JW. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs. 2013; 31: 85-91.
27. Bauman JE, Arias-Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013; 49: 461-467.
28. Ramalingam SS, Owonikoko T, Behera M, et al. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol. 2013; 8: 369-372.
29. Lemaitre F, Bezian E, Goldwirt L, et al. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit. 2012; 34: 686-694.
30. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1588-1595.
31. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2012; 42: 903-911.
32. Moes DJ, Press RR, den Hartigh J, et al. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012; 51: 467-480.